The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer.
about
Methyltransferase G9a promotes cervical cancer angiogenesis and decreases patient survival.Multi-omics analysis reveals that ornithine decarboxylase contributes to erlotinib resistance in pancreatic cancer cells.Pharmacoepigenetics and pharmacoepigenomics of gastrointestinal cancers.Targeting Epigenetic Aberrations in Pancreatic Cancer, a New Path to Improve Patient Outcomes?Preprogramming therapeutic response of PI3K/mTOR dual inhibitor via the regulation of EHMT2 and p27 in pancreatic cancer
P2860
The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 August 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The histone methyltransferase ...... sistance in pancreatic cancer.
@en
The histone methyltransferase ...... sistance in pancreatic cancer.
@nl
type
label
The histone methyltransferase ...... sistance in pancreatic cancer.
@en
The histone methyltransferase ...... sistance in pancreatic cancer.
@nl
prefLabel
The histone methyltransferase ...... sistance in pancreatic cancer.
@en
The histone methyltransferase ...... sistance in pancreatic cancer.
@nl
P2093
P2860
P356
P1433
P1476
The histone methyltransferase ...... sistance in pancreatic cancer.
@en
P2093
Chi-Wen Luo
Li-Tzong Chen
Mei-Ren Pan
Ming-Chuan Hsu
Wen-Chun Hung
Yan-Shen Shan
P2860
P304
61136-61151
P356
10.18632/ONCOTARGET.11256
P407
P577
2016-08-12T00:00:00Z